Ambitious drug developer Oxford Genome Sciences (OGeS) has secured private equity funding of an undisclosed sum from a syndicate of investors. The funding round was led by Catapult Growth Fund and included South East Growth Fund and Oxford Capital Partners.
Ambitious drug developer Oxford Genome Sciences (OGeS) has secured private equity funding of an undisclosed sum from a syndicate of investors. The funding round was led by Catapult Growth Fund and included South East Growth Fund and Oxford Capital Partners.
With the funding, OeGS aims to develop personalised drug therapies for cancer and Alzheimer’s disease. The deal is the first investment for Catapult, a newly-launched £30 million fund. The other two funders have backed OeGS before.
Chief executive Christian Rohlff says that the ‘additional funds provide us with financing visibility for the next three years’.
Oxford-based OGeS was founded in 2004. During the past year, the company has entered into partnerships with businesses in the therapeutic and diagnostic industries, such as US company Bayer HealthCare Diagnostics.
